Business
Sisram Medical Reports First-Half 2025 Results: Injectables Surge as AI-Powered EBD Strengthens Segment Positioning
Sisram Medical Ltd (the "Company" or "Sisram", 1696.HK; referred to collectively with its subsidiaries as the "Group"), a global consumer wellness group, featuring a distinguished synergistic ecosystem of business building blocks and consumer-focused approaches including Energy-Based Devices (EBD), and Injectables, alongside other complementary offerings, today announced its unaudited consolidated interim results for the six months ended June 30, 2025 (the "Reporting Period").
About this update from Sisram Medical Ltd.
[{"type":"text","content":"HONG KONG, Aug. 20, 2025 /PRNewswire/ -- Sisram Medical Ltd (the "Company" or "Sisram", 1696.HK; referred to collectively with its subsidiaries as the "Group"), a global consumer wellness group, featuring a distinguished synergistic ecosystem of business building blocks and consumer-focused approaches including Energy-Based Devices (EBD), and Injectables, alongside other complementary offerings, today announced its unaudited consolidated interim results for the six months ended June 30, 2025 (the "Reporting Period").","length":562,"tagName":"p"},{"type":"text","content":"FINANCIAL HIGHLIGHTS","length":20,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Revenue was US$165.5 million, representing a decrease of 1.9% YoY","length":65,"tagName":"p"}]},{"val":[{"type":"text","content":"Revenue of Injectables line achieved US$14.4 million, representing a significant increase of 218.1% YoY","length":103,"tagName":"p"}]},{"val":[{"type":"text","content":"Revenue in the international market[1] was US$108.9 million, up 7.1% YoY. In APAC, revenue achieved a 17.6% increase YoY","length":120,"tagName":"p"}]},{"val":[{"type":"text","content":"Gross margin decreased from 62.4% to 60.0%, mainly due to a shift toward higher-cost core-professionals and sophisticated products with premium materials, along with lower North America revenue share","length":199,"tagName":"p"}]},{"val":[{"type":"text","content":"Adjusted net profit was US$12.0 million, down 28.1% YoY","length":55,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":542,"olType":false},{"type":"text","content":"Advancing EBD Market Potential with AI powered Innovations for an Intelligent, Integrated Approach to Aesthetic Care During the Reporting Period, Sisram reinforced its leadership in non-invasive body contouring with peer-reviewed validation of the Alma Accent Prime platform in the Nature Scientific Reports, creating new commercial opportunities globally. Alma Harmony also exceeded expectations, further strengthening the Company's position in advanced aesthetic solutions.","length":485,"tagName":"p"},{"type":"text","content":"Expanding beyond energy-based technologies, Sisram introduced innovations that build an intelligent, integrated infrastructure across the patient journey. In North America, Unive...